文章摘要
血清miR-338-3p，HDAC9在缺血性卒中患者中的表达及与短期预后的相关性研究
Expression of serum miR-338-3p and HDAC9 in patients with ischemic stroke and their correlation with short-term prognosis
投稿时间：2024-12-20  修订日期：2024-12-20
DOI：
中文关键词: 微小RNA（miR）-338-3p  组蛋白去乙酰化酶9  缺血性卒中  预后
英文关键词: MicroRNA (miR) -338-3p  Histone deacetylase 9  Ischemic stroke  Prognosis
基金项目:
作者单位邮编
董永军 延安市中医医院神经外科 716000
摘要点击次数: 17
全文下载次数: 0
中文摘要:
      目的：探讨微小RNA（miR）-338-3p、组蛋白去乙酰化酶9（HDAC9）在缺血性卒中（IS）患者血清中的表达，以及与患者短期预后的相关性。方法：选取2021年1月~2023年6月在本院（延安市中医医院联合延安大学附属医院）进行治疗的80例IS患者作为研究对象，根据患者发病3个月后预后情况将其分为预后良好组（n=49）和预后不良组（n=31）；另选取80例健康体检者为对照组。比较各组血清miR-338-3p、HDAC9水平；多因素Logistic回归分析IS患者短期预后的影响因素；ROC曲线分析血清miR-338-3p、HDAC9对IS患者短期预后的预测价值。结果：与对照组相比，IS组miR-338-3p水平显著降低，HDAC9水平显著升高（P<0.05）。IS患者预后不良组miR-338-3p水平显著低于预后良好组，NIHSS评分、HDAC9水平显著高于预后良好组（P<0.05）。Target Scan Human网站预测结果显示，miR-338-3p与HDAC9有靶向结合位点。HDAC9、入院时NIHSS评分是IS患者短期预后的危险因素（P<0.05），miR-338-3p是保护因素（P<0.05）。血清miR-338-3p、HDAC9二者联合预测IS患者短期预后的AUC为0.966，敏感性为96.77%，特异性为87.76%，二者联合优于血清miR-338-3p、HDAC9各自单独预测（Z二者联合-miR-338-3p=2.014、Z二者联合-HDAC9=2.052，P=0.044、0.040）。结论：IS患者血清miR-338-3p水平显著降低，HDAC9水平显著升高，二者联合对IS患者短期预后具有较高的预测价值。
英文摘要:
      Objective: To investigate the expression of microRNA-338-3p and histone deacetylase 9 (HDA9) in the serum of patients with ischemic stroke (IS), and their correlation with short-term prognosis. Methods: From January 2021 to June 2023, 80 patients with IS who underwent treatment in our hospital were regarded as the study subjects. Based on their prognosis three months after onset, they were separated into a good prognosis group (n=49) and a poor prognosis group (n=31); another 80 healthy individuals were regarded as the control group. The serum levels of miR-338-3p and HDAC9 were compared among different groups; multivariate Logistic regression was applied to analyze the influencing factors of short-term prognosis in IS patients; ROC curve was applied to analyze the predictive value of serum miR-338-3p and HDAC9 for the short-term prognosis of IS patients. Results: Compared with the control group, the miR-338-3p level in the IS group was obviously reduced, while the HDAC9 level was obviously increased (P<0.05). The miR-338-3p level in the poor prognosis group was obviously lower than that in the good prognosis group, while the NIHSS score and HDAC9 level were obviously higher than those in the good prognosis group (P<0.05). The prediction results from Target Scan Human website showed that miR-338-3p had a targeted binding site with HDAC9. HDAC9 and NIHSS score at admission were risk factors for short-term prognosis in IS patients (P<0.05), while miR-338-3p was a protective factor (P<0.05). The combined prediction of serum miR-338-3p and HDAC9 for short-term prognosis in IS patients had an AUC of 0.966, sensitivity of 96.77%, and specificity of 87.76%, the combination of the two was better than the individual prediction of serum miR-338-3p and HDAC9 (Z combination - miR-338-3p=0.014, Z combination - HDAC9=2.052, P=0.044, 0.040). Conclusion: The serum miR-338-3p level in IS patients is obviously decreased, while HDAC9 level is obviously increased. The combination of the two has high predictive value for the short-term prognosis of IS patients.
View Fulltext   查看/发表评论  下载PDF阅读器
关闭